# OnCo record optune (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/optune/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "optune" ;
  schema:name "Optune / Optune Pax (TTFields)"@en ;
  schema:description "Optune is a wearable device delivering electric fields that disrupt cell division. It is approved for glioblastoma and, in 2026, pancreatic cancer."@en ;
  schema:url <https://onco.cc/drugs/optune/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tumor_treating_fields> ;
  schema:citation <https://en.wikipedia.org/wiki/Tumor_treating_fields>, <https://doi.org/10.1200/JCO-25-00746> ;
  onco:status "approved" ;
  onco:modality "Device (tumour treating fields)" ;
  schema:alternateName "Optune" ;
  onco:approval "US 2011: Recurrent glioblastoma (newly diagnosed 2015)", "US 2024: Metastatic NSCLC after platinum with PD-1 or docetaxel", "US 2026: Locally advanced pancreatic cancer with chemotherapy", "EU 2015: CE mark (GBM); pancreatic and NSCLC CE marks 2024-26" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/locally-advanced-pdac/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/mesothelioma/> ;
  onco:technologies <https://onco.cc/technologies/ttfields/> ;
  onco:companies <https://onco.cc/companies/novocure/> .